Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Conditions

Locally Advanced Oral Squamous Cell Carcinoma · Oral Squamous Cell Carcinoma (OSCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Jinsong Li, MD, PhD) · wanglsh25@mail2.sysu.edu.cn · 81332471
Contact: Study coordinator (Qunxing Li, MD, PhD) · liqx73@mail.sysu.edu.cn · 81332661
Liansheng Wang, PhD Candidate (Sub-investigator)

Study leads

Jinsong Li, MD, PhD
Principal Investigator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma.

Oral Squamous Cell Carcinoma · Locally Advanced Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)Recruiting

Changsha, China

Neoadjuvant Immunochemotherapy for LAOSCC

Oral Squamous Cell Carcinoma · Locally Advanced Head and Neck Carcinoma

Abroad (travel likely)RecruitingPHASE3

Shanghai, China

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma

Oral Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE3

Shenzhen, China · Wuhan, China

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Oral Squamous Cell Carcinoma · Neoadjvant Therapy · Anti-PD-1

Abroad (travel likely)RecruitingPHASE2, PHASE3

Shanghai, China